Hormone replacement therapy

Drug and Therapeutics Bulletin

Volumn 34, Issue 11, 1996, Pages 81-84

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; ESTROGEN; GESTAGEN; PHENYTOIN;

ALZHEIMER DISEASE; BREAST CANCER; BREAST DISEASE; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; ESTROGEN THERAPY; FEMALE; HORMONE SUBSTITUTION; HUMAN; INTRAVAGINAL DRUG ADMINISTRATION; ISCHEMIC HEART DISEASE; MENOPAUSAL SYNDROME; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE OSTEOPOROSIS; SHORT SURVEY; STROKE; THROMBOEMBOLISM; TRANSDERMAL DRUG ADMINISTRATION; VAGINA BLEEDING; VAGINA DISCHARGE; WEIGHT GAIN;

EID: 0029850522     PISSN: 00126543     EISSN: None     Source Type: Journal    
DOI: 10.1136/dtb.1996.341181     Document Type: Short Survey

References (32)

1. Hope S, Rees MCP. Why do British women start and stop hormone replacement therapy? J Br Menopause Soc 1995; October: 26-8.
2. Pearce J, Hawton K, Blake F Psychological and sexual symptoms associated with the menopause and the effects of hormone replacement therapy. Br J Psychiatry 1995; 167: 163-73.
3. Women and coronary heart disease. DTB 1996; 34: 28-30.
4. Falkeborn M, Persson I, Terent A, Adami H-O, Lithell H, Bergström R. Hormone replacement therapy and the risk of stroke. Follow-up of a population-based cohort in Sweden Arch Intern Med 1993; 153: 1201-9.
5. Finucane FF, Madans JH, Bush TL, Wolf PH, Kleinman JC. Decreased risk of stroke among postmenopausal hormone users. Results from a national cohort. Arch Intern Med 1993; 153: 73-9.
6. Managing osteoporosis. DTB 1996; 34: 45-8
7. Paganini-Hill A, Henderson VW. Estrogen deficiency and risk of Alzheimer's disease in women Am J Epidemiol 1994; 140: 256-61.
8. Tang M-X, Jacobs D, Stern Y et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 1996; 348: 429-32.
9. Howell A, Baildam A, Bundred N, Evans G, Anderson E. 'Should I take HRT, doctor?'. Hormone replacement therapy in women at increased risk of breast cancer and in survivors of the disease. J Br Menopause Soc 1995; October: 9-17.
10. Marsden J, Sacks NPM. Hormone replacement therapy and breast cancer. Endocrine-Related Cancer 1996; 3: 81-97.
11. Cobleigh MA, Berris RF, Bush T et al for the Breast Cancer Committees of the Eastern Cooperative Oncology Group. Estrogen replacement therapy in breast cancer survivors. A time for change. JAMA 1994; 272: 540-5.
12. DiSaia PJ, Grosen EA, Kurosaki T, Gildea M, Cowan B, Anton-Culver H. Hormone replacement therapy in breast cancer survivors: a cohort study. Am J Obstet Gynecol 1996; 174: 1494-8.
13. Loprinzi CL, Michalak JC, Quella SK et al. Megestrol acetate for the prevention of hot flashes. N Engl J Med 1994; 331: 347-52.
14. Powles TJ, Hickish T, Casey S, O'Brien M. Hormone replacement after breast cancer. Lancet 1993; 342: 60-1 [letter].
15. Daly E, Vessey MP, Hawkins MM, Carson JL, Gough P, Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996; 348: 977-80.
16. Jick H, Derby LE, Wald Myers M, Vasilakis C, Newton KM. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 1996; 348: 981-3.
17. Grodstein F, Stampfer MJ, Goldhaber SZ et al Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet 1996; 348: 983-7.
18. Ettinger B, Selby J, Citron JT, Vangessel A, Ettinger VM, Hendrickson MR. Cyclic hormone replacement therapy using quarterly progestin. Obstet Gynecol 1994; 83: 693-700.
19. Woodruff JD, Pickar JH for The Menopause Study Group, Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone. Am J Obstet Gynecol 1994; 170: 1213-23.
20. Hirvonen E, Salmi T, Puolakka J et al. Can progestin be limited to every third month only in postmenopausal women taking estrogen? Maturitas 1995; 21: 39-44.
21. The Writing Group for the PEPI Trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1996; 275: 370-5.
22. Udoff L, Langenberg P, Adashi EY. Combined continuous hormone replacement therapy a critical review. Obstet Gynecol 1995; 86: 306-16.
23. McKinlay SM, Brambilla DJ, Posner JG. The normal menopause transition. Maturitas 1992; 14: 103-15.
24. Advice on contraception around the menopause. DTB 1992; 30; 95-6.
25. Andersson K, Mattsson L-A, Rybo G, Stadberg E. Intrauterine release of levonorgestrel - a new way of adding progestogen in hormone replacement therapy. Obstet Gynecol 1992; 79: 963-7.
26. Oral contraception in the perimenopause. DTB 1991; 29: 3-4.
27. Benedek-Jaszmann LJ. Long-term placebo-controlled efficacy and safety study of ORG OD 14 in climacteric women. Maturitas 1987; suppl 1: 25-33.
28. Tibolone (Livial) - a new steroid for the menopause. DTB 1991; 29: 77-8.
29. Martin PL, Yen SSC, Burnier AM, Hermann H. Systemic absorption and sustained effects of vaginal estrogen creams. JAMA 1979; 242: 2699-700.
30. Handa VL, Bachus KE, Johnston WW, Robboy SJ, Hammond CB. Vaginal administration of low-dose conjugated estrogens: systemic absorption and effects on the endometrium. Obstet Gynecol 1994; 84: 215-8.
31. Bachmann G. The estradiol vaginal ring - a study of existing clinical data. Maturitas 1995; 22 (suppl): S21-9.
32. Nilsson K, Heimer G. Low-dose oestradiol in the treatment of urogenital oestrogen deficiency - a pharmacokinetic and pharmacodynamic study. Maturitas 1992; 15: 121-7.